Glenn Sblendorio

Board Member Chairman at Nanoscope Therapeutics Inc.

Glenn Sblendorio is a seasoned professional with extensive experience in finance, healthcare, and real estate investment. Currently serving as Managing Member of SBL IG of Florida, LLC, Glenn specializes in real estate investment across commercial, industrial, and residential properties in Florida. In the healthcare sector, Glenn has held various board positions, including Board Member and Chair roles at Amicus Therapeutics and Mineralys Therapeutics, and currently serves as Chairman of the Board at Nanoscope Therapeutics. Previously, Glenn was President and CEO of Iveric Bio, and held executive leadership roles in companies such as The Medicines Company, Eyetech Pharmaceuticals, Sony Interactive Entertainment, and Roche. Educational credentials include an Advanced Management Program from Harvard Business School and an MBA in Finance from Fairleigh Dickinson University.

Location

Jupiter, United States

Links

Previous companies


Org chart

This person is not in the org chart


Teams

This person is not in any teams


Offices


Nanoscope Therapeutics Inc.

1 followers

Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells. Update: June, 2021: Nanoscope Therapeutics Announces FDA Approval of IND for Phase 2b clinical trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with Retinitis Pigmentosa


Employees

11-50

Links